Global Endometriosis Industry

NEW YORK, Nov. 23, 2016 /PRNewswire/ -- This report analyzes the worldwide markets for Endometriosis in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 38 companies including many key and niche players such as -

AbbVie Inc.
AEterna Zentaris Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Bayer HealthCare Pharmaceuticals, Inc.

Read the full report: http://www.reportlinker.com/p04368326-summary/view-report.html

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1 Disclaimers.............. I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW.............. II-1 Endometriosis Statistics Fact Sheet II-1 A Quick Market Primer..............II-2 Poor Efficacy and Safety Profiles of Existing Drugs Lead to Unmet Medical Needs..............II-3 Key Endometriosis Drugs on the Market II-3 Table 1: Leading Endometriosis Drugs on the Market (2015): Percentage Market Share Breakdown of Depo Provera, Eligard, Lupron, Visanne, Zoladex, and Others (includes corresponding Graph/Chart).............. II-4 The Pipeline Review.............. II-4 Key Endometriosis Drugs in the Pipeline: 2016 II-5 Current and Future Analysis..............II-6 Emerging Treatment for Endometriosis & Endometrial Cancer II-6 Global Awareness Campaigns and Efforts II-7

2. ENDOMETRIOSIS & ITS TREATMENT - AN OVERVIEW II-9 Introduction.............. II-9 Occurrence of Endometriosis in Women II-9 Causes and Symptoms.............. II-10 Causes.............. II-10 Estrogen Theory.............. II-10 Müllerianosis Theory..............II-10 Retrograde Menstruation Theory II-10 Coelomic Metaplasia Theory..............II-11 Hereditary Factors..............II-11 Environmental Factors..............II-11 Dioxin Behavior in the Body II-11 Birth Defects.............. II-12 Other Causes.............. II-12 Symptoms of Endometriosis..............II-12 Reasons for Pain due to Endometriosis II-13 Endometriosis and Infertility..............II-13 Kinds of Endometriosis..............II-13 Reproductive Area Endometriosis II-13 Uterosacral/Presacral Nerve Endometriosis II-13 Cul-de-Sac ("Pouch of Douglas") Endometriosis II-14 Gastrointestinal Endometriosis..............II-14 Pleural (lung/chest cavity/diaphragmatic) Endometriosis II-14 Urinary Tract (kidneys, ureters, bladder and urethra) Endometriosis.............. II-14 Skin Endometriosis.............. II-14 Sciatic Endometriosis..............II-14 Stages of Endometriosis..............II-14 Diagnosis of Endometriosis..............II-15 Major Diagnostic Techniques..............II-15 Pelvic Exam.............. II-15 Laparoscopy.............. II-15 Other Diagnostic Procedures..............II-16 A New Non-invasive Test for the Diagnosis of Endometriosis II-16 Endometriosis Markers..............II-16 Counseling of patients..............II-16 Recurrence of Endometriosis..............II-16 Endometriosis & Infertility..............II-17 Miscarriage.............. II-17 Endometriosis & Thyroid Autoimmunity II-17 Relationship between Endometriosis and Autoimmune Disease II-17 Endometriosis & Cancer..............II-17 Associations & Research Centers..............II-17 The Endometriosis Association II-18 Endometriosis Research Center II-18

3. TREATMENT OF ENDOMETRIOSIS..............II-19 Endometriosis & Available Treatment Options II-19 Endometriosis Treatment: In a Nutshell II-20 I.Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) II-21 II.Hormonal Therapy.............. II-21 Gonadotropin Releasing Hormone (Gnrh) Agonists II-21 Select Major GnRH-Agonists for Endometriosis Treatment II-22 Lupron, Zoladex and Synarel - The Major Drugs II-22 Abbott's Lupron® (Leuprorelin) II-22 AstraZeneca's Zoladex® (Goserelin) II-22 Pfizer's Synarel (Nafarelin Acetate) II-23 Add-back Medication..............II-23 Progestogens.............. II-23 Select Major Progestins for Endometriosis Treatment II-24 Combined Oral Contraceptive Pill II-24 Danazol and Other Suppressive Steroids II-24 Chinese Herbs - More Effective than Danazol or Gestrinone II-24 Aromatase Inhibitors..............II-25 III.Non-hormonal Therapy..............II-25 Anti-Angiogenic Agents..............II-25 Selective COX-2 Inhibitors..............II-25 TNF-Alpha Inhibitors..............II-25 IV.Surgical Techniques..............II-25 V.Complementary Therapies..............II-26 Long-term Approach to Pain..............II-26 Lifestyle Modifications..............II-26 Chinese Herbs.............. II-26 Treatment for Endometriosis-related Infertility II-26 Hormonal Treatment.............. II-27 Minimal to Mild Endometriosis..............II-27 Moderate-Severe Endometriosis..............II-27 Surgical Treatment.............. II-27 Minimal-Mild Endometriosis..............II-27 Moderate-Severe Endometriosis..............II-27 Treatment for Ovarian Endometriosis II-28 Surgical Vs. Medicinal Interventions II-28 Medicinal Interventions..............II-28 Advantages.............. II-28 Disadvantages.............. II-28 Surgery.............. II-28 Advantages.............. II-28 Disadvantages.............. II-29 In-vitro Fertilization..............II-29 Other Treatment.............. II-29

4. SELECT CLINICAL TRIALS/PRODUCT INNOVATIONS & APPROVALS II-30 Virexxa Receives FDA Clearance to Proceed to Phase II II-30 OBE2109 by ObsEva Receives IND Clearance II-30 Galena Biopharma Presents Phase 1/2a Data on Endometrial Cancer Immunotherapies..............II-30 AbbVie and Neurocrine Report Positive Phase 3 Trial Data of Elagolix.............. II-30 ValiRx Plc to Begin Endometriosis Clinical Research with its VAL201.............. II-30 Aurobindo Pharma Receives FDA Approval to Market Tablets for Endometriosis Treatment..............II-30 Lumenis to Introduce UltraPulse DUO CO2 laser system and FemTouch Solution..............II-31 Bayer Launches Phase II Trials of vilaprisan for Endometriosis Treatment.............. II-31 Nippon Shinyaku Conducts Phase I Evaluation of NS 580 for Endometriosis Therapy..............II-31 Teleflex to Showcase its Surgical Solutions for Endometriosis II-31 ValiRx Plc Receives Patent Grant for VAL201 II-31 Hologic Launches NovaSure 6mm Endometrial Ablation System II-31 Endometriosis Research Foundation Releases Standardized Data Tools.............. II-31 ESHRE Develops App for Endometriosis Management II-32

5. RECENT INDUSTRY ACTIVITY..............II-33 Takeda and Roivant Partner to Form Myovant II-33 Evotec-Bayer Collaboration Reaches Important Clinical Milestones for Endometriosis Therapy II-33 ObsEva and Kissei Pharmaceutical Enter Into Collaboration Agreement for KLH-2109..............II-33 Aeterna Zentaris Adds New Clinical Site for Endometrial Cancer Therapy Phase 3 Trial..............II-33 VolitionRx Enters Into Collaboration with University of Oxford for Endometriosis Clinical Solution II-33 SRI International and Nobelpharma Enter Into Licensing Agreement for SR16234..............II-34

6. FOCUS ON SELECT GLOBAL PLAYERS..............II-35 AbbVie Inc. (US).............. II-35 AEterna Zentaris Inc. (Canada) II-35 Astellas Pharma Inc. (Japan)..............II-35 AstraZeneca Plc. (UK)..............II-36 Bayer HealthCare Pharmaceuticals, Inc. (US) II-36 Debiopharm Group (Switzerland) II-37 Evotec AG (Germany).............. II-37 Kissei Pharmaceutical Co., Ltd. (Japan) II-38 Neurocrine Biosciences, Inc. (US) II-38 ObsEva SA (Switzerland)..............II-38 Pfizer, Inc. (US).............. II-39 Repros Therapeutics, Inc. (US) II-39 Roivant Sciences Ltd. (US)..............II-39 Takeda Pharmaceutical Company Limited (Japan) II-40 ValiRx Plc (UK).............. II-40

7. GLOBAL MARKET PERSPECTIVE..............II-41 Table 2: World Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) II-41

Table 3: World Historic Review for Endometriosis Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) II-42

Table 4: World 14-Year Perspective for Endometriosis Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).............. II-43

III. MARKET

1. THE UNITED STATES.............. III-1 A.Market Analysis.............. III-1 United States: The Largest Market for Endometriosis III-1 Endometriosis Associations Increase Awareness III-1 Newer Diagnostic Methods Yet to Expand Across the Country III-1 Key Endometriosis Drugs on the Market III-2 Product Launches..............III-2 Strategic Corporate Developments III-3 Select Key Players..............III-4 B.Market Analytics..............III-6 Table 5: The US Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-6

Table 6: The US Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-7

2. CANADA.............. III-8 A.Market Analysis.............. III-8 Product Launch.............. III-8 Strategic Corporate Development III-8 Select Key Players..............III-8 B.Market Analytics..............III-10 Table 7: Canadian Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-10

Table 8: Canadian Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-11

3. JAPAN.............. III-12 A.Market Analysis.............. III-12 Clinical Trial.............. III-12 Select Key Players..............III-12 B.Market Analytics..............III-14 Table 9: Japanese Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-14

Table 10: Japanese Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-15

4. EUROPE.............. III-16 Market Analysis.............. III-16 Table 11: European Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region/Country - France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-17

Table 12: European Historic Review for Endometriosis Drugs by Geographic Region/Country - France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-18

Table 13: European 14-Year Perspective for Endometriosis Drugs by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of European Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart)..............III-19

4a. FRANCE.............. III-20 A.Market Analysis.............. III-20 Programmes to Maintain Endometriosis Database III-20 B.Market Analytics..............III-21 Table 14: French Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-21

Table 15: French Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-22

4b. GERMANY.............. III-23 A.Market Analysis.............. III-23 Clinical Trial.............. III-23 Strategic Corporate Development III-23 Evotec Ag - A Key Player..............III-23 B.Market Analytics..............III-24 Table 16: German Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-24

Table 17: German Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-25

4c. ITALY.............. III-26 Market Analysis.............. III-26 Table 18: Italian Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-26

Table 19: Italian Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-27

4d. THE UNITED KINGDOM..............III-28 A.Market Analysis.............. III-28 Product Launches..............III-28 Select Key Players..............III-28 B.Market Analytics..............III-29 Table 20: The UK Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-29

Table 21: The UK Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-30

4e. SPAIN.............. III-31 Market Analysis.............. III-31 Table 22: Spanish Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-31

Table 23: Spanish Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-32

4f. REST OF EUROPE.............. III-33 A.Market Analysis.............. III-33 Product Launches..............III-33 Strategic Corporate Developments III-33 Select Key Players..............III-34 B.Market Analytics..............III-35 Table 24: Rest of Europe Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-35

Table 25: Rest of Europe Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-36

5. ASIA-PACIFIC.............. III-37 A.Market Analysis.............. III-37 Proteomics Being Researched for Endometriosis Therapeutics (Australia).............. III-37 Select Key Player.............. III-37 B.Market Analytics..............III-38 Table 26: Asia-Pacific Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-38

Table 27: Asia-Pacific Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-39

6. REST OF WORLD.............. III-40 A.Market Analysis.............. III-40 Product Launch.............. III-40 B.Market Analytics..............III-41 Table 28: Rest of World Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-41

Table 29: Rest of World Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-42

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 38 (including Divisions/Subsidiaries - 40)

The United States (11) Canada (3) Japan (6) Europe (15) - France (1) - Germany (3) - The United Kingdom (2) - Rest of Europe (9) Asia-Pacific (Excluding Japan) (4) Middle-East (1)
Read the full report: http://www.reportlinker.com/p04368326-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-endometriosis-industry-300368306.html

SOURCE Reportlinker